RVC has published its Annual Report 2015, Value of Fundamentals. This report presents the company’s performance in creating both financial and non-financial development tools for building an innovation ecosystem in Russia, as well as its achievements in supporting the progress of the National Technology Initiative (NTI).
The NeuroMax Company invested by Maxwell Biotech venture fund created with the participation of the RVC capital, announces the inclusion of the first volunteers in the open, prospective clinical trial of the first phase of the AQU-005 drug for the treatment of neuropathic pain of various etiologies
RetroSense Therapeutics, a portfolio company of RBV Capital Fund, created with the participation of the RVC capital, has been recognized as one of the most promising startups in ranking of the 50 Smartest Companies in 2016
On June 18, as part of SPIEF, a business breakfast was held on the following topic: "The role of IT in the implementation of the National Technology Initiative", organized jointly by RVC, RAEC, and RUSSOFT.
The Regional Practical Consulting Sessions (RPCS) are Free RVC intensive sessions intended for representatives of innovative companies, the scientific community, universities, professionals and investors — are held from June to September in twenty cities of Russia and CIS countries
The biotechnological company "Gepatera" invested by the Fund "Maxwell Biotech" that is established with the participation of the RVC capital presented the results of clinical trials of the drug Myrcludex B in the Journal of Hepatology
Biotechnology company NeuroMax invested by Maxwell Biotech fund set up with participation of RVC capital has completed qualification of patients for phase 3 of the clinical trial of BNV-222 innovation drug